ArticleChina CDC weekly2026
Putative Adverse Outcome Pathway in Kashin-Beck Disease Suggested by Lipidomics and Network Toxicology - Xi'an City, Shaanxi Province, China, 2023-2025.
Article in China CDC weekly, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
What is already known about this topic?: Lipids are key mediators in cartilage degeneration. While T-2 toxin exposure drives Kashin-Beck disease (KBD), systematic metabolic comparisons between KBD and osteoarthritis (OA) are lacking. What is added by this report?: KBD and OA share cartilage lipid alterations linked to ferroptosis, but KBD exhibits unique changes indicating severe oxidative stress. Furthermore, prostaglandin-endoperoxide synthase 2 (PTGS2) was identified as the candidate molecular target potentially involved in T-2 toxin-induced cartilage damage. What are the implications for public health practice?: Uncovering the adverse outcome pathway of T-2 toxin exposure clarifies KBD pathogenesis. Targeting the PTGS2-mediated signaling pathway may provide a potential strategy for clinical intervention and disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.